771 reports of this reaction
3.9% of all ADO TRASTUZUMAB EMTANSINE reports
#1 most reported adverse reaction
DISEASE PROGRESSION is the #1 most commonly reported adverse reaction for ADO TRASTUZUMAB EMTANSINE, manufactured by Genentech, Inc.. There are 771 FDA adverse event reports linking ADO TRASTUZUMAB EMTANSINE to DISEASE PROGRESSION. This represents approximately 3.9% of all 19,599 adverse event reports for this drug.
Patients taking ADO TRASTUZUMAB EMTANSINE who experience disease progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE PROGRESSION is moderately reported among ADO TRASTUZUMAB EMTANSINE users, representing a notable but not dominant share of adverse events.
In addition to disease progression, the following adverse reactions have been reported for ADO TRASTUZUMAB EMTANSINE:
The following drugs have also been linked to disease progression in FDA adverse event reports:
DISEASE PROGRESSION has been reported as an adverse event in 771 FDA reports for ADO TRASTUZUMAB EMTANSINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE PROGRESSION accounts for approximately 3.9% of all adverse event reports for ADO TRASTUZUMAB EMTANSINE, making it one of the most commonly reported side effect.
If you experience disease progression while taking ADO TRASTUZUMAB EMTANSINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.